Navigation Links
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Date:11/2/2009

WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile. Overall, 20% of patients ultimately achieved a complete response and 28% of patients achieved an overall objective response (complete response or partial response). Ninety two percent of the responses are durable as defined as lasting at least 6 months, and the majority are ongoing, with a range of 18 to 40 months. Responses were observed in patients with all stages of disease, including the complete resolution of visceral deposits. The study results were made available online today on the JCO website and will be published in the December 2009 print edition. The Phase 2 study was led by Dr. Neil N. Senzer of The Mary Crowley Cancer Research Center, Dallas, TX.

"The high percentage of durable complete responses in this study suggests that this therapy has the potential to provide long term benefit to responding patients, potentially including cures," said Dr. Neil N. Senzer of The Mary Crowley Cancer Research Center, Dallas, TX. "OncoVEX (GM-CSF) offers significant promise in providing a real advance in the treatment of a disease where there are few if any effective treatment options, particularly when coupled with a relatively benign side effect profile."

"In addition to use in more advanced patients, these encouraging results suggest OncoVEX (GM-CSF) has the potential to be used to intervene in the early stages of metastatic disease where it might act to reduce the high rate of progression to widespread diseas
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
2. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
6. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
7. Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call
8. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
9. Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
10. Stryker Announces Change in Chairman of the Board of Directors
11. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  An International Trade Commission (ITC) ruling issued Friday ... device, Taiwanese device manufacturer APEX continues to infringe ResMed ... ) is the innovation leader and pioneer in designing ... "Our research and development teams are ... of comfort, performance and efficacy," said David Pendarvis ...
(Date:7/21/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... announces that the United States International Trade Commission (USITC) ... newly designed XT series continuous positive airway pressure (CPAP) ... the patent claims asserted by ResMed, one of Apex,s ... an upgraded iCH water tank to the market in ...
(Date:7/18/2014)... 2014 Hanger, Inc. (NYSE: HGR ) ... operations for the quarter ended June 30, 2014, on Tuesday, ... to discuss these results is scheduled to begin at 9:00 ... participate should call 1-877-662-6095. A replay will be available until ... ID # 44683027. About Hanger, Inc. – Built ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
(Date:7/21/2014)... iFitDress.com, a famous company of wedding dresses and special ... of 2014 glitter evening dresses . Moreover, the ... gowns. , iFitDress.com is one of the most loved ... in the recent years, not just because of its ... amicable services offered on its website. , The ...
(Date:7/21/2014)... MA (PRWEB) July 21, 2014 What ... extramarital affair have in common? You can find them ... Heart! The novel's main character, Miranda, lives on Martha’s ... meets Clay, a wealthy New Yorker, and becomes entangled ... of the Heart challenges readers to think about what ...
(Date:7/21/2014)... July 21, 2014 Executives from ... specializing in private healthcare practices, will participate in ... They will be showcasing their state-of-the-art capabilities and ... practices all over the United States as the ... continues to increase. Advice Media’s presence at IACA ...
(Date:7/21/2014)... 2014The Associated Press-NORC Center for Public Affairs Research has ... public,s opinions about what it means to be a ... survey, funded by the Robert Wood Johnson Foundation, sheds ... of their health care and doctors, as well as ... care decisions. The survey produces new and actionable data ...
(Date:7/21/2014)... 2014 (HealthDay News) -- Good parenting and life ... from low-income families, a new study suggests. ... and can lead to a number of illnesses, ... problems in both childhood and adulthood involve excessive ... heart disease, allergies and some cancers," study author ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2
... past have argued about the implications of Hormone Replacement Therapy ... A new study, however, has gone further to show that ... developing breast cancer// if they consumed alcoholic beverages. ,The ... pattern and on whether they were on HRT currently or ...
... have found that people who take anti-depressants to relieve ... developing gastrointestinal bleeding. The study which was conducted over ... were compared for hospitalizations due to upper GI bleeding ... on selective serotonin reuptake inhibitors, or SSRIs, were 3.6-times ...
... by a Diabetes Research Centre in India has shown that ... had considerable improvement when they followed safe practices advised by ... doctors discovering that many patients came to the Centre with ... their lives. They decided that a little change in lifestyle ...
... called 'HERS' conducted by researchers of the University of California, ... that Hormone Replacement Therapy (HRT) may be able to reduce ... develop diabetes as well. ,The study involved some women ... had "impaired fasting glucose" - a condition with some ...
... 61 previous studies of blood pressure and cardiovascular disease, which ... regardless of age and even if readings are in the ... reducing risk of strokes and heart attacks. ,The study ... that out of the 120,000 who died, 56,000 suffered fatal ...
... Chairman and Managing Director of Eli Lilly and Co., India, ... cut in the company's human insulin product 'Huminsulin', that its ... market by the end of this year. He added that ... use of human insulin products and the phasing out of ...
Cached Medicine News:Health News:Women on HRT should avoid alcohol 2
... a multipurpose agarose, has been developed for ... and separation of high molecular weight DNA ... a high gel strength agarose ( 1800 ... the use of low concentrations of agarose ...
Inquire...
... Agarose is a premium agarose used for ... This agarose produces clear sharp bands, with ... lot of UltraClean Forensic Agarose is tested ... activity, RNase activity and DNA contamination. ...
... specifically formulated for high resolution of small ... This standard melting temperature agarose can resolve ... bp difference in size. UltraPure™ Agarose ... for better handling and improved clarity for ...
Medicine Products: